Cardiovascular health during and after cancer therapy

Kathryn J. Ruddy, Shruti R. Patel, Alexandra S. Higgins, Saro H. Armenian, Joerg Herrmann

Research output: Contribution to journalReview articlepeer-review


Certain cancer treatments have been linked to specific cardiovascular toxicities, including (but not limited to) cardiomyopathy, atrial fibrillation, arterial hypertension, and myocarditis. Radiation, anthracyclines, human epidermal growth factor receptor 2 (Her2)-directed therapies, fluoropyrimidines, platinums, tyrosine kinase inhibitors and proteasome inhibitors, immune checkpoint inhibitors, and chimeric antigen-presenting (CAR)-T cell therapy can all cause cardiovascular side effects. Management of cardiovascular dysfunction that occurs during cancer therapy often requires temporary or permanent cessation of the risk-potentiating anti-neoplastic drug as well as optimization of medical management from a cardiovascular standpoint. Stem cell or bone marrow transplant recipients face unique cardiovascular challenges, as do patients at extremes of age.

Original languageEnglish (US)
Article number3737
Pages (from-to)1-16
Number of pages16
Issue number12
StatePublished - Dec 2020


  • Anthracycline
  • Cardio-oncology
  • Congestive heart failure
  • Myocarditis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Cardiovascular health during and after cancer therapy'. Together they form a unique fingerprint.

Cite this